Table 5 Serial changes in DAIBD, CRP level and clinical response

Baseline

109.3 ± 32.5 (N = 48)

3.91 ± 4.93 (N = 44)

Week 4

50.3 ± 39.1 (N = 33)^**

27 (81.8)

2.20 ± 4.02 (N = 38)^**

Week 8

39.3 ± 36.1 (N = 40)^**

35 (87.5)

1.41 ± 3.33 (N = 39)^**

Week 12

47.6 ± 43.7 (N = 33)^**

30 (90.9)

1.26 ± 2.03 (N = 43)^**

Week 28

35.8 ± 37.1 (N = 30)^**

27 (90.0)

1.08 ± 2.18 (N = 40)^**

Week 56

33.5 ± 29.3 (N = 29)^**

26 (89.7)

1.20 ± 2.46 (N = 40)^**

Early termination

110.0 ± 21.2 (N = 2)

0 (0.0)

4.25 ± 2.94 (N = 4)

Serial changes in patients who were previously treated with infliximab

Baseline

104.0 ± 40.9 (N = 10)

3.48 ± 2.58 (N = 8)

Week 4

40.6 ± 29.6 (N = 8)^**

6 (75)

1.43 ± 1.97 (N = 10)

Week 8

32.0 ± 30.9 (N = 10)^**

9 (90)

0.36 ± 0.43 (N = 8)^**

Week 12

49.3 ± 62.5 (N = 9)^**

6 (66.7)

1.50 ± 2.44 (N = 10)

Week 28

23.3 ± 32.4 (N = 9)^**

8 (88.9)

0.51 ± 0.63 (N = 9)^**

Week 56

20.0 ± 23.5 (N = 9)^**

8 (88.9)

0.63 ± 0.60 (N = 10)^**